{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:56:15Z","timestamp":1762930575706,"version":"3.45.0"},"reference-count":12,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"Pfizer Oncology"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2025,5,4]]},"DOI":"10.1080\/17474086.2025.2492886","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T16:15:51Z","timestamp":1744906551000},"page":"399-407","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Real-world (RW) study of outcomes for acute myeloid leukemia (AML) patients treated with glasdegib or venetoclax in US community oncology practices"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3442-7320","authenticated-orcid":false,"given":"Kristin M. Zimmerman","family":"Savill","sequence":"first","affiliation":[{"name":"Real-World Evidence and Insights","place":["Dublin, USA"]},{"name":"Flatiron Health","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan K.","family":"Kish","sequence":"additional","affiliation":[{"name":"Real-World Evidence and Insights","place":["Dublin, USA"]},{"name":"Flatiron Health","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choo Hyung","family":"Lee","sequence":"additional","affiliation":[{"name":"Real-World Evidence and Insights","place":["Dublin, USA"]},{"name":"Individual Contributor, Carmel, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prathamesh","family":"Pathak","sequence":"additional","affiliation":[{"name":"Real-World Evidence and Insights","place":["Dublin, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4276-8821","authenticated-orcid":false,"given":"Paul","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1445-8138","authenticated-orcid":false,"given":"Alexander","family":"Russell-Smith","sequence":"additional","affiliation":[{"name":"Pfizer R&D Ltd","place":["Sandwich, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5929-0466","authenticated-orcid":false,"given":"Ajeet","family":"Gajra","sequence":"additional","affiliation":[{"name":"Real-World Evidence and Insights","place":["Dublin, USA"]},{"name":"Hematology Oncology Associated","place":["Central New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,4,20]]},"reference":[{"key":"e_1_3_7_2_1","unstructured":"Kolitz JE. Overview of acute myeloid leukemia in adults. 2022 Jan 28. Available from: https:\/\/www.uptodate.com\/contents\/overview-of-acute-myeloid-leukemia-in-adults?search=%E2%80%A2%09Acute%20myeloid%20leukemia&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1"},{"key":"e_1_3_7_3_1","volume-title":"SEER cancer statistics review, 1975\u20132016","author":"Howlader N","year":"2019","unstructured":"Howlader N, Noone AM, Krapcho M, et al, editors. SEER cancer statistics review, 1975\u20132016. Bethesda (MD): National Cancer Institute; 2019."},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000486228"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0312-9"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1283032"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2824"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04465-4"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2018.11.002"},{"issue":"4","key":"e_1_3_7_11_1","first-page":"1121","article-title":"Clinical endpoints in oncology \u2013 a primer","volume":"11","author":"Delgado A","year":"2021","unstructured":"Delgado A, Guddati AK. Clinical endpoints in oncology \u2013 a primer. Am J Cancer Res. 2021;11(4):1121\u20131131.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100332"},{"key":"e_1_3_7_13_1","unstructured":"U.S. Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics guidance for industry. 2018 [cited 2024 Apr 5]. Available from: https:\/\/www.fda.gov\/media\/71195\/download"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2025.2492886","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:54:22Z","timestamp":1762930462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2025.2492886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,20]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,4]]}},"alternative-id":["10.1080\/17474086.2025.2492886"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2025.2492886","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"type":"print","value":"1747-4086"},{"type":"electronic","value":"1747-4094"}],"subject":[],"published":{"date-parts":[[2025,4,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}